



IBA Notice of First Half 2014 Results and Conference Call

Louvain-la-Neuve, Belgium, 14 August, 2014 - IBA ([Ion Beam Applications S.A.](#)), the world's leading provider of proton therapy solutions for the treatment of cancer, will publish its consolidated results for the first half of 2014 on **Thursday, 28 August 2014 at 07.00 CET**.

In addition to the press release, Olivier Legrain, Chief Executive Officer, and Jean-Marc Bothy, Chief Financial Officer, will host a conference call and webcast to present the first half results, followed by a Q&A session.

This conference will be held on 28 August 2014 at 14:00 CET / 13:00 BST / 08.00 EDT and may be accessed on the home page or on the "investor relations" page of IBA website at www.iba-worldwide.com. If you would like to participate in the Q&A, please dial (PIN code 69403589#):

| | |
|----------|------------------|
| Belgium: | +32 2 404 03 05 |
| UK: | +44 207 750 9926 |
| NL: | +31 207 133 488 |
| LU: | +352 278 601 66 |
| US: | +1 914 885 0779 |
| FR: | +33 172 040 033 |

Shortly after the call, the presentation used in connection with the conference call webcast will be available on the IBA website.

To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.

###

About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.

The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room systems. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing more than 1,000 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company



Press release |

is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange Euronext. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

For Further information please contact:

IBA

Marie Gahylle

Corporate assistant

Tel: +32 10 47 58 90

InvestorRelations@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications

Amber Bielecka, Mary-Jane Elliott, Matthew Neal, Ivar Milligan

+44 (0) 207 920 2333

IBA@consilium-comms.com